Chroniques génomiques - Une thérapie très attendue… et un prix exorbitant !

Jordan, Bertrand

doi:10.1051/medsci/2023003

dc.contributor.author	Jordan, Bertrand	-
dc.date.accessioned	2023-12-28T15:11:34Z
dc.date.available	2023-12-28T15:11:34Z
dc.date.issued	2023
dc.identifier.citation	Jordan, Bertrand ; Une thérapie très attendue… et un prix exorbitant ! : Chroniques génomiques, Med Sci (Paris), Vol. 39, N° 2 ; p. 187-190 ; DOI : 10.1051/medsci/2023003
dc.identifier.issn	1958-5381
dc.identifier.uri	http://hdl.handle.net/10608/14485
dc.description.abstract	After many years of development, a gene therapy for haemophilia B has demonstrated effectiveness and durability, at least over a time span of three years. It has just been approved (as Hemgenix®) by the FDA in the USA and by the EMA in the EU. However, the multimillion price tag of this treatment is a serious problem for healthcare systems and for patients, and raises a number of thorny issues about marketing practices of the pharmaceutical industry.	en
dc.language.iso	fr
dc.publisher	EDP Sciences
dc.relation.ispartof	Forum
dc.rights	Article en libre accès - License CC BY 4.0	fr
dc.rights	Médecine/Sciences - Inserm - SRMS	fr
dc.rights.uri	http://creativecommons.org/licenses/by/4.0
dc.source	M/S. Médecine sciences [ISSN papier : 0767-0974 ; ISSN numérique : 1958-5381], Vol. 39, N° 2; p. 187-190
dc.subject.mesh	Humains	fr
dc.subject.mesh	Agrément de médicaments	fr
dc.subject.mesh	Industrie pharmaceutique	fr
dc.title	Chroniques génomiques - Une thérapie très attendue… et un prix exorbitant !	fr
dc.title.alternative	A long-awaited - but prohibitively expensive - therapy	en
dc.type	Article
dc.contributor.affiliation	Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la génomique) , 13007 Marseille , France
dc.identifier.doi	10.1051/medsci/2023003
dc.identifier.pmid	36799758